Turning Immunosuppressive Tumors to Immunostimulatory: Nerofe and Doxorubicin's Impact | Oncota

Oncotarget published this trending research paper on July 1, 2023 in Volume 14, entitled, “Transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors by Nerofe and Doxorubicin" by researchers from Immune System Key (ISK) Ltd., Jerusalem 9746009, Israel; Department of Bio-Informatics, Lev Academic Center (JCT), Jerusalem 91160, Israel.
#cancer #cancerresearch #colorectalcancer #research #researchpaper #openaccess #openscience #peerreview #journal #publication #meded #publishing #apoptosis #tumors

DOI - https://doi.org/10.18632/oncotarget.28467

Correspondence to - Yoram Devary - ydevary@immunesk.com

Abstract

Members of the rat sarcoma viral oncogene (RAS) subfamily KRAS are frequently mutated oncogenes in human cancers and have been identified in pancreatic ductal, colorectal, and lung adenocarcinomas. In this study, we show that a derivative of the hormone peptide Tumor Cell Apoptosis Factor (TCApF), Nerofe™ (dTCApFs), in combination with Doxorubicin (DOX) substantially reduces viability of tumor cells. It was observed that the combination of Nerofe and DOX downregulated KRAS signaling via miR217 upregulation, resulting in enhanced apoptosis of tumor cells. In addition, the combination of Nerofe and DOX also resulted in activation of the immune system against tumor cells, manifested by an increase in the immunostimulatory cytokines IL-2 and IFN-γ as well as the recruitment of NK cells and M1 macrophages to the tumor site.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.c....om/details/email_upd

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - Colorectal cancer, KRAS, apoptosis, hormone peptide, endoplasmic reticulum stress

About Oncotarget

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

• Category

  Colorectal Cancer